Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-7-27
pubmed:abstractText
We used doxorubicin-based chemotherapy as a clinical model for oxidative assault. Study recruited 23 breast cancer patients and collected blood samples before (T0), at 1 (T1) and 24 hours (T24) after treatment administration. Measurements included protein carbonyl content (PPCC), malondialdehyde (MDA), and alpha- and gamma-tocopherols in plasma and total glutathione content in erythrocytes (erGSHt). In all subjects, PPCC and MDA levels did not change. erGSHt levels increased at T24 by 8% (p=0.03). Levels of alpha, gamma, and total tocopherols progressively decreased by 7%-15% (p <0.05). In subjects with low erGSHt levels (below median), PPCC mean levels progressively increased from 0.35 (T0) to 0.56 (T1) and 0.72 nmol carbonyl/mg protein (T24) (p =0.2). These results indicate that (1) plasma MDA is not a sensitive biomarker in humans; (2) PPCC potentially may be used, if antioxidant reserves are taken into account; (3) antioxidant reserves play an important role in the reaction to oxidative stress.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-10802213, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-11313279, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-12142263, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-12767102, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-12814619, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-1462166, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-15155533, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-15169927, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-15721980, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-1596995, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-17596778, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-18379219, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-18455517, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-2842038, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-3162516, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-3338183, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-8015470, http://linkedlifedata.com/resource/pubmed/commentcorrection/19476408-9351979
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1366-5804
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
321-5
pubmed:dateRevised
2010-9-27
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration.
pubmed:affiliation
Duke Comprehensive Cancer Center, Durham, NC 27710, USA. dora.ilyasova@duke.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural